Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Anyone have any idea about CASI Pharm?
Saw this on another message board , seems another company bought a bunch of CASI PHARM. stock on 3/3/17. New SEC Filing for CASI:
Form SC 13G/A, No. 0001144204-17-012744
What is this about http://stocknewsflow.com/895051_000114420417012744_0001144204-17-012744
Any updates or thoughts on CASI Pharm.
More Bad news for this company, quite glad I sold out pre split and jumped some shares into CASI Pharm..
Something could be a brewing. The stock had a nice jump in pps and volume. I addition to that it is peculiar that their website is also down. Could all be GREAT news is coming out. GLTA Gronk
This stock has very low volume and gets knocked down on 100-300 shares traded at a time. Seems the shares are how to come by. I am holding & waiting the news to come out.
hopefully news comes soon on the CFDA. that would spike up the pps
Any idea why the recent rise in pps?
New to this stock. What does it have to offer in terms of growth and earnings. Also any thoughts this stock could ever reach 20 cents?
Thinking of buying in but can it be explained what aspire is buying in means? I want to load up on this stock or Casi Pharm.
Thinking of buying in but can it be explained what aspire is buying in means? I want to load up on this stock or Casi Pharm.
Is there a lot of shorting going on with this stock?
Got out totally yesterday. The voting will be a joke like last time. Once this dog does it r/s, it will be brought down over the year. The pipeline line will drag on for years just to pay the BOD's salaries. GLTA and I hope you do well, Gronk(Go PATS)
Is this r/s going to be a 1/10 or 1/100?
Interesting video only problem it is back from February well before any news. hopefully there will be a change of news this week. GLTA
Not feeling anything positive coming out for Galena. Not saying to sell but yuck this company is turning into a real mess! GLTA
Looks as though the mm's just ran it up midweek for the shorties to profit. Maybe news someday but when? Why is Roche still involved if their patent is expiring? Unless, they plan a buyout of Galena before that patent expires.
Well, nice move today. Can't say it was a pump & dump because management has not put any news out. Zach's write up is the usual trash they write up on a great deal of stocks so not really a pump from trashy Zach's. Is it a MM move to get investors excited to walk it back down? Maybe? IMO, there is some positive news lurching from the company itself, but WHEN is the question. If there is another nice rise the next 2 days leading into the weekend , Monday will be the info/pr day. GLTA, Trade wisely.
Maybe someone can answer this for me...I also look at the Yahoo message board at times. I just gave it a glance and the shorts are still there knocking the snout out of Galena. My question is: Since the stock got clobbered on last week's news why would they even bother, is there really something behind the scenes the shorty hedge funds know ?
Mark Schwartz presentation
here's the link for this years presentation.
Nice write up from Roth Capital
Roth Capital Maintains Buy on Galena Biopharma Inc (GALE) and Mast Therapeutics Inc (MSTX) Following Clinical Updates
SHARE ON:
Jason Cohen, Editor — June 7, 2016, 11:53 AM EDT
New insights emerge in the biotech sector as Galena Biopharma Inc (NASDAQ:GALE) presented an update on GALE-301 at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting, while Mast Therapeutics Inc (NYSEMKT:MSTX) got no love from investors after announcing a delay in reporting of phase III trial (EPIC) results for vepoloxamer for the treatment of vaso-occlusive crisis in patients with sickle cell disease. Roth Capital analysts weigh in on the news. Let’s take a closer look.
Galena Biopharma Inc
Roth Capital analyst Joseph Pantginis reiterated a Buy rating on shares of Galena with a $5.00 price target, after the cancer drug maker provided an update at the ASCO on its GALE-301 vaccine program, which is currently being studied in a Phase I/II study for the prevention of recurrent ovarian or endometrial cancers.
Pantginis noted, “We see the positive correlations between vaccine dose or schedule and rate of recurrence as positive indicators of the vaccine’s potential. While management does not consider the vaccine a core asset at this time, the data could guide future development of the program, and we see optionality in the asset.”
“We note that while the data are still immature (mOS not reached), we believe the data here (vaccine dose and boost strategy) could be used to inform the design of future studies. However, as mentioned previously, the company is now entirely focused on the broad NeuVax program, led by the Phase III PRESENT study in adjuvant breast cancer. The interim analysis for the Phase III PRESENT study in adjuvant breast cancer is expected in 2Q16,” the analyst continued.
Does anyone know if the proxy will be mailed or sent to your broker and when?
Some more interesting tibits that the pps will likely increase with the options market and the increase activity:
GALE's call options are in high demand once again, changing hands at 17 times their average daily pace -- with call volume docked in the 100th annual percentile.The January 2017 and 2018 series are hot, accounting for the top four of GALE's 10 most active options. Shorter-term traders are also targeting the $2.50 level, and appear to be buying to open the stock's July 2.50 call. Buyers of this call are looking for Galena Biopharma Inc (NASDAQ:GALE) to extend its rally through the close on Friday, July 15, when back-month options expire.
There are 4 institutional investors that routinely grow their share in GALE. This week the final one of the 4 posted their March 31 position. These four are Vanguard, Blackrock, State Street and Northern Trust. Combined they have increased their holdings from 16 million shares on March 31, 2015 to 20 million shares on March 31, 2016. Respectively they increased 41%, 15%, 35% and 37%.
Another interesting read:
Galena Biopharma Inc
Galena Biopharma is currently advancing in interim analysis of its key pipeline, NeuVax, a product aimed at treating cancer of epidermal growth factor receptor (HER2). The drug is currently going through Phase III trial, PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low-to-Intermediate HER2 Expression with NeuVax Treatment).
In light of this, FBR Analyst Vernon T. Bernardino provides speculation regarding supporting trends in favor of NeuVax as a stock catalyst.
Bernardino notes that the potential upside from NeuVax, a “significant near-term milestone” is undervalued. He explains the interim analysis of safety and futility expected in 2Q:16 is expected to be positive and “transformative” for the company, elaborating further that the interim should result in “lowered risk for NeuVax’s progression through late stage testing.”
The analyst remains ambitious towards the completion of the study, with hopes that the Independent Data Monitoring Committee (IDMC) will ease the process. Bernardino recalls, “in March 2016, PRESENT reached the 70th qualifying disease-free survival event, which is defined as a recurrence of breast cancer (BC), occurrence of another cancer, or death from any cause. Recall also that this interim analysis is a prespecified look at safety and futility on the first 70 adjudicated events and will evaluate the probability of the study to achieve its prespecified objectives.”
He explains further, “We expect the IDMC will recommend PRESENT “keep going,” and although a low probability, we think any observation that hints at NeuVax activity could be a major catalyst for the stock.”
The analyst understands that the upcoming IDMC interim review may result only in a comment on the safety and futility of NeuVax treatment. However, he remains optimistic that an encouraging remark may not only accelerate PRESENT, but other pipelines as well. He explains, “positive IDMC recommendation also has the potential to provide insight into the 300-patient combination study in node-positive, HLA A2+/A3+ BC. In particular, we think a positive IDMC recommendation for PRESENT’s continuation could point to a similar conclusion (a safety look is expected in late 2016) that the HLA A2+/A3+ BC combination trial indicates positive trends and should also continue.”
Bernardino reiterates an Outperform rating on GALE with a price target of $5.00.
Just saw this on My-Gale.com very interesting;
http://www.wndu.com/content/news/NeuVax-Breast-Cancer-Vaccine-tested-at-Memorial-Cancer-Center-375739991.html
At the moment, Galena Biopharma (NASDAQ: GALE) sharholders would suggest they have one such gold mine in NeuVax. The cancer immunotherapy vaccine is being studied in late-stage trials and is designed to act as an adjuvant therapy to prevent the reccurrence of breast cancer in patients with low-to-moderate HER2-expression. Cancer immunotherapies are garnering tons of attention right now since they work side-by-side with your immune system to give it a better shot at locating and destroying cancer cells.
\
Source: Galena Biopharma.
In phase 2 studies, cancer recurred in just 5.6% of the NeuVax intent-to-treat group after 60 months. By comparison, cancer recurred in 25.9% of the control group that wasn't given NeuVax, resulting in a statistically significant 78.4% clinical benefit. The trial results also demonstrated that NeuVax had few side effects and was well tolerated by trial participants.
If NeuVax is approved it could transform post-surgical treatment for low-to-moderate HER2-expression breast cancer patients, and it would likely make Galena profitable in short order. Based on its current market value, Galena would also turn out to be incredibly inexpensive if NeuVax is approved, which is why today's shareholders are so excited about its prospects.
Good job Esedu with the updates... The MM's really playin their manipulation games today with the pps and the short sale numbers were at 60.9% today.
Thanks Apollo that is what I was referring to. Schwab what the heck is wrong with them?
AN old spin off from Galena. Thoughts were this about Galena doing this r/s but it is not but RXi Pharm.
RXi Pharmaceuticals Announces Reverse Stock Split
BY PR Newswire
— 2:15 PM ET 04/15/2016
MARLBOROUGH, Mass., April 15, 2016 /PRNewswire/ -- RXi Pharmaceuticals Corporation , a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs, today announced a reverse stock split of its shares of common stock at a ratio of 1-for-10. The reverse stock split will become effective at 12:01 a.m. Eastern Time on April 18, 2016, and shares of RXi Pharmaceuticals ( RXII
Loading... Loading...
) common stock will trade on a post-split basis on the Nasdaq Capital Market under the Company's existing trading symbol, "RXII," at the market open on April 18, 2016. The new CUSIP number for the Company's common stock following the reverse stock split will be 74979C501.
Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
As previously reported, RXi Pharmaceuticals ( RXII
Loading... Loading...
) currently has until May 2, 2016 to regain compliance with the Nasdaq Stock Market's minimum bid price requirement, and, to regain compliance, RXi Pharmaceuticals ( RXII
Loading... Loading...
) common stock must have a minimum bid price per share of at least $1.00 for 10 consecutive business days. The principal reason for the reverse stock split is to increase the per share trading price of the Company's common stock in order to help ensure a share price high enough to satisfy the $1.00 per share minimum bid price requirement. However, there can be no assurance that the reverse stock split will have the desired effect of sufficiently raising the bid price of RXi Pharmaceuticals ( RXII
Loading... Loading...
) common stock for the required period.
"The current depression of share prices for small biotech companies has caused several of these companies to consider the use of a reverse split as a way to maintain a share price that is in line with the listing requirements of the national stock exchanges," said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals ( RXII
Loading... Loading...
), adding that, "the Board and management of RXi Pharmaceuticals ( RXII
Loading... Loading...
) consider their NASDAQ listing as an important tool to maintain a strong position for value creation through possible business or corporate development transactions. At the same time, this listing is also a key component for private and institutional investors in making their investment decisions in our Company."
The reverse stock split was approved by RXi Pharmaceuticals' ( RXII
Loading... Loading...
) stockholders at a special meeting held on April 14, 2016 and the Board of Directors was authorized to implement the reverse stock split and determine the ratio of the split within a range of not less than 1-for-2 or greater than 1-for-40. Thereafter, the Board of Directors determined to fix the ratio for the reverse stock split at 1-for-10.
At the effective time of the reverse stock split, every ten (10) shares of RXi Pharmaceuticals ( RXII
Loading... Loading...
) common stock will be combined into one (1) share of RXi Pharmaceuticals ( RXII
Loading... Loading...
) common stock. This will reduce the Company's issued and outstanding common stock from approximately 65.3 million shares to approximately 6.5 million shares. The reverse stock split will also proportionately adjust outstanding options issued under the Company's equity incentive plan and outstanding overallotment rights and warrants to purchase common stock. The number of authorized shares will remain unchanged, resulting in an increase of the number of authorized shares not outstanding.
No fractional shares of common stock will be issued as a result of the reverse stock split and instead holders will receive a cash payment in lieu of fractional shares to which they would otherwise be entitled. After the effective time of the reverse stock split, shareholders with shares held in certificate form will receive a Letter of Transmittal and instructions from RXi Pharmaceuticals' ( RXII
Loading... Loading...
) transfer agent, Computershare, Inc. Shareholders that hold shares in book-entry form or hold their shares in brokerage accounts are not required to take any action and will see the impact of the reverse stock split reflected in their accounts. Beneficial holders of RXi Pharmaceuticals ( RXII
Loading... Loading...
) common stock are encouraged to contact their bank, broker, custodian or other nominee with questions regarding procedures for processing the reverse stock split.
Additional information regarding RXi Pharmaceuticals' ( RXII
Loading... Loading...
) reverse stock split is available in the definitive proxy statement, filed March 7, 2016, and Form 8-K filed today by RXi Pharmaceuticals ( RXII
Loading... Loading...
) with the U.S. Securities and Exchange Commission.
About RXi Pharmaceuticals Corporation ( RXII
Loading... Loading...
)
RXi Pharmaceuticals Corporation ( RXII
Loading... Loading...
) is a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs. Building on the pioneering work of RXi's Scientific Advisory Board Chairman and Nobel Laureate Dr. Craig Mello, our discovery and clinical development programs are based on our proprietary RNAi (sd-rxRNA) platform and Samcyprone™, a topical immunomodulator. Our clinical development programs include RXI-109, an sd-rxRNA, for the treatment of dermal and ocular scarring, and Samcyprone™ for the treatment of such disorders as warts, alopecia areata, non-malignant skin tumors and cutaneous metastases of melanoma. RXi's robust pipeline, coupled with an extensive patent portfolio, provides for multiple product and business development opportunities across a broad spectrum of therapeutic areas. We are committed to being a partner of choice for academia, small companies, and large multinationals. We welcome ideas and proposals for strategic alliances, including in- and out-licensing opportunities, to advance and further develop strategic areas of interest. Additional information may be found on the Company's website, www.rxipharma.com.
Trying to pick up some jan2018 options all week , no luck yet.
GREAT to hear Galena LED the way for biotechs today
Fresh from Nasdaq .
Monday Sector Leaders: Drugs, Biotechnology Stocks
By BNK Invest, April 04, 2016, 01:22:56 PM EDT
In trading on Monday, drugs shares were relative leaders, up on the day by about 3.4%. Leading the group were shares of Flexion Therapeutics ( FLXN ), up about 17.5% and shares of Cytrx ( CYTR ) up about 15.2% on the day.
Also showing relative strength are biotechnology shares, up on the day by about 3.1% as a group, led by Galena Biopharma ( GALE ), trading higher by about 16.1% and Nantkwest ( NK ), trading higher by about 13.6% on Monday.
8 funds bought stakes while 22 increased positions. They now own 31.02 million shares or 11.17% more from 27.90 million shares in 2015Q2.
Hoxton Financial Inc. holds 0.04% of its portfolio in Galena Biopharma Inc for 50,000 shares. Dumont & Blake Investment Advisors Llc owns 30,675 shares or 0.03% of their US portfolio. Moreover, Group One Trading L.P. has 0.03% invested in the company for 1.26 million shares. The Rhode Island-based Compton Capital Management Inc Ri has invested 0.01% in the stock. Ladenburg Thalmann Financial Services Inc, a Florida-based fund reported 154,369 shares.
Out of 5 analysts covering Galena Biopharma (NASDAQ:GALE), 5 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Galena Biopharma was the topic in 10 analyst reports since August 7, 2015 according to StockzIntelligence Inc.
This Adam Feuerstein will have to be Prosecuted because he is posting in the Public False and Misleading information that can effect a stocks price and it's Investors Correct decisions. This is much worse than pumping it up on Actual and Factual News. He should rot next to M. Ahn. No misleading news is good on either side. We longs are telling the truth on this board and are going by Company presentations, real News and Real Clinical Trial Outcomes, How dare Adam say PH II failed for Neuvax when it moved into PHASE III and even over enrolled to help more Women. He is out of his Mind. Don't believe his Lies. Believe FACTS!!
Why Dr. Sinkule, Why NOW?
Dr. Sinkule designed and processed NeuVax Trials and SPA protocols. He's the one most responsible for direct discourse with the FDA throughout the years NeuVax was evolving. I want to know, as directly as possible from the one person Most Responsible for NeuVax FDA-processes: "What's the outlook & what are the chances of an early NeuVax Provisional Approval?"
Tuesday's Conference Call with Dr. Joseph Sinkule will cover this, plus other topics. See Conference Call participation details at the my-gale(plus standard suffix) site. My-gale regularly hosts Conference Call special guests. Respectfully, Dan
Interesting read from the YMB
NEWS: ABC ACTION NEWS SAYS, " 'NUEVAX AND HERCEPTIN' VACCINE CAN CUT BREAST CANCER RISK IN HALF"!
TAMPA, FL - Every three minutes, a woman is diagnosed with breast cancer. Every thirteen minutes, a woman dies of the disease.
For the women and men fighting the battle, the fear is that it could always come back.
Most recurrences happen five years after breast cancer treatments, which why Moffitt Cancer Center is working to fight that battle.
At any given time, 160 therapeutic trials are going on at the hospital.
Although researchers have made great strides, 40,000 patients die every year of the disease.
Some of those have fought breast cancer more than once.
Dr. Hatem Soliman says his new study is working to bring the rate of developing a tumor again down to zero.
“The vaccine treatment is for a period of three years,” said Soliman.
Right now, he’s looking for women and men who just completed the early stages of breast cancer treatments have the HER-2 protein.
Those are the patients with the most aggressive form of cancer.
“This is an example of a cancer cell that we can find floating in the blood. We know it's a cancer cell because we stain it with particular colors,” said Soliman.
If patients qualify, they will receive a combination of the NeuVax vaccine and the prescription drug Herceptin, hoping it will be a one-two punch to ward off cancer cells.
Early trials have shown the vaccine to cut the risk of recurrence in half.
“The vaccine is very safe, very well tolerated and does not cause any side effects when administered to women with breast cancer,” said Soliman.
Soliman says if this trial is successful, in five years women and men could be one step closer to never having to worry about breast cancer striking twice.
If you would like to sign up for the clinical trial call 813-745-4933. Less
Schwartz from page 2 of the CC transcript:
"In addition to the PRESENT trial, we have two ongoing investigators sponsored trials, one co-funded by Genentech/Roche and the other by the department of defense with NeuVax combination with trastuzumab or HERCEPTIN. This year, we look forward to presenting our first data set from our NeuVax plus HERCEPTIN or what we call H&N Trial in the HER2 1+/2+ breast cancer patients as seen on the second line of the pipeline slide. This preliminary safety data is expected to be presented at a scientific congress in the fourth quarter."
3/21/16 Dr. david Fujii says, "NEUVAX IS WORKING" IN PHASE 3 TO SHOW 78% OR GREATER EFICACY!!
The 78% efficacy recurrence curve, equivalent to the Phase 3 Target Patient Population efficacy, now crosses the 70th event threshold in December 2015, while the 100% efficacy recurrence curve now crosses that threshold in May 2016. Dr. Mark Schwartz, President and CEO of Galena, has publicly stated that the 70th breast cancer recurrence event is now expected in late March or early April 2016 (Year-End 2015 Earnings Conference Call, March 10, 2016) - this corresponds to a mean efficacy of 95% or greater in the current simulation model. While this forecast is slightly less aggressive than the original analysis, it derives from a broader and more suitable base and does not require a 2% increase in peak hazard rate to fit the baseline breast cancer DFS rate for the current PRESENT trial. As an independent and unambiguous corroboration of the positive course for the trial, Bijan Nejadnik, Executive Vice President and Chief Medical Officer of Galena Biopharma, announced on the Year-End 2015 Earnings Conference Call that "the overall rate of occurrence is very much in line in what has been expected previously."
JUST another reason for NOT selling your shares:
This is from page 9 of the Seeking Alpha transcript for GALE's CC on 3/10/16:
Operator: Our next question is from Reni Benjamin with Raymond James:
"Hi good afternoon. Thanks for taking the questions. I guess just thinking about the interim analysis I know in the past that you guys talked about maybe the powering assumptions to the entire study and thinking about a recurrence rate of 23% on a control and 15% on treatment I think that's what I have in my notes. Can you give us maybe some sense as to what kind of assumptions are going into the interim analysis and I guess where I'm going with this is, is that possible or have you put it into the calculations some sort of analysis that prevents you from sort of stopping the study of feudality too early. Maybe 70 events is just not enough to see a separation in the curves. Just any sort of additional details you might be able to provide."
Answer from GALE's Dr. Bijan Nedajnik:
"Thanks Ren. yes you are right about the original assumptions and when we looked at the rate of occurrence right now although we cannot say lets group what is the tripping assignment. The overall rate of occurrence is very much in line in what has been expected previously. So we have all the reasons to believe that we are on track for that and I'm not sure if you had any additional questions, but I should say that as far as the assumptions are concern within the interim analysis we do not expect at least with the numbers that we have that those to be wrong.
The interim analysis itself of course consists looking at separation of the rate, difference of the rate between the control group and the treatment group and within that knowing that certain time has passed, but the study is not over. Looking at that separation to calculate the probability of this study of succeed. And that hurdle have been fixed at 15% which is called a conditional power and that conditional power is very much low hurdle, we do not anticipate any problem there at all."